Moderna invests in R&D as Spikevax sales fall

1 August 2024

mRNA specialist Moderna (Nasdaq: MRNA) has reported a decline in revenues for the second quarter of 2024, taking in $241 million, down from $344 million in the same period last year.

The company's net loss was $1.3 billion, equating to a loss per share of $3.33, compared to a net loss of $1.4 billion and a loss per share of $3.62 in the second quarter of 2023.

The decline in revenue was primarily driven by reduced sales of Spikevax, Moderna's COVID-19 vaccine, reflecting the anticipated shift to a seasonal market.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology